Could It Happen Again?: The Björk-Shiley Convexo-Concave Heart Valve Story

Most readers of “Twenty-Five–Year Experience With the Bjork-Shiley Convexoconcave Heart Valve: A Continuing Clinical Concern” in this issue of Circulation have not heard of the valve.1 Many elements of its story parallel those of cerivastatin2,3⇓ and rofecoxib,4 but with a twist: Recalling a heart valve may entail greater risks than leaving a possible “time bomb” in place. The Bjork-Shiley story raises many questions about balancing the benefits of drugs and devices with their risks to public safety. For example: See p 2850 My personal involvement began when a lawyer for Shiley, Inc, with a biostatistical degree read our account of the Braunwald-Cutter heart valve and wanted to understand why the University of Alabama at Birmingham and the Mayo Clinic decided to prophylactically remove every one.5 Subsequently, I served on scientific panels, spearheaded a multi-institutional effort to quantify the risks of prosthesis explant,6 and suggested ways to use this information for the tough decision making ahead.7 The Bjork-Shiley heart valve, developed by Shiley, Inc, in collaboration with Dr Viking Bjork of Sweden, was …

[1]  Drummond Rennie,et al.  Postmarketing surveillance--lack of vigilance, lack of trust. , 2004, JAMA.

[2]  D. Rennie,et al.  Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals. , 1998, JAMA.

[3]  James G. Chandler,et al.  Reoperation on prosthetic heart values. Patient-specific estimates of in-hospital events. , 1995, The Journal of thoracic and cardiovascular surgery.

[4]  William J. Blot,et al.  Twenty-Five–Year Experience With the Björk-Shiley Convexoconcave Heart Valve: A Continuing Clinical Concern , 2005, Circulation.

[5]  Nancy A. Dreyer,et al.  Patient Factors Associated With Strut Fracture in Björk-Shiley 60° Convexo-Concave Heart Valves , 1995 .

[6]  James G. Chandler,et al.  Utilization of manufacturers' implant card data to estimate heart valve failure. , 1993, The Journal of heart valve disease.

[7]  E. Blackstone,et al.  The performance of the Braunwald-Cutter aortic prosthetic valve. , 1977, The Annals of thoracic surgery.

[8]  B. Strom.  Potential for conflict of interest in the evaluation of suspected adverse drug reactions: a counterpoint. , 2004, JAMA.

[9]  M Kallewaard,et al.  Which manufacturing characteristics are predictors of outlet strut fracture in large sixty-degree Björk-Shiley convexo-concave mitral valves? The Björk-Shiley Study Group. , 1999, The Journal of thoracic and cardiovascular surgery.

[10]  N. Dreyer,et al.  Patient factors associated with strut fracture in Björk-Shiley 60 degrees convexo-concave heart valves. , 1995, Circulation.

[11]  J. Habbema,et al.  Decision Analyses for Prophylactic Replacement of the Björk-Shiley Convexo-concave Heart Valve: , 2000, Medical decision making : an international journal of the Society for Medical Decision Making.

[12]  Eric J Topol,et al.  Failing the public health--rofecoxib, Merck, and the FDA. , 2004, The New England journal of medicine.

[13]  E. Blackstone,et al.  Recommendations for prophylactic removal of heart valve prostheses. , 1992, The Journal of heart valve disease.

[14]  U. Kaul,et al.  Thrombotic obstruction of Bjork-Shiley valves--diagnostic and surgical considerations. , 1984, International journal of cardiology.

[15]  H Reul,et al.  Strut fracture mechanisms of the Björk-Shiley convexo-concave heart valve. , 1999, The Journal of heart valve disease.

[16]  B. Psaty,et al.  Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. , 2004, JAMA.

[17]  A. C. Eberhardt,et al.  Acoustic characterization of mechanical valve condition and loading. , 1995, The Journal of heart valve disease.

[18]  W S Pierce,et al.  In vivo accuracy of two radiographic systems in the detection of Björk-Shiley convexo-concave heart valve outlet strut single leg separations. , 1998, The Journal of thoracic and cardiovascular surgery.

[19]  Anil Jain,et al.  Responding to the Rofecoxib Withdrawal Crisis: A New Model for Notifying Patients at Risk and Their Health Care Providers , 2005, Annals of Internal Medicine.